▶ 調査レポート

世界のバイオ医薬品用発酵システム市場(~2027):製品別、用途別、エンドユーザー別、地域別

• 英文タイトル:Biopharmaceutical Fermentation System Market Research Report by Product, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。世界のバイオ医薬品用発酵システム市場(~2027):製品別、用途別、エンドユーザー別、地域別 / Biopharmaceutical Fermentation System Market Research Report by Product, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2303L199資料のイメージです。• レポートコード:MRC2303L199
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、233ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:バイオ
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査レポートでは、2021年に135.1億ドルであった世界のバイオ医薬品用発酵システム市場規模が2022年に145.3億ドルとなり、2027年までに年平均7.72%拡大して211.2億ドルに達すると予測されています。本書では、バイオ医薬品用発酵システムの世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(下流プロセス製品、上流プロセス製品)分析、用途別(抗生物質、モノクローナル抗体、プロバイオティクス、組換えタンパク質)分析、エンドユーザー別(バイオ医薬品企業、受託研究機関、食品産業、研究開発機関)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、Becton、Danaher Corporation、Dickinson and Company、F. Hoffmann-La Roche Ltd、GE Healthcare、Lonza、Merck KGaA、Nova Biomedicals、Sartorius Stedim、Thermo Fisher Scientificなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のバイオ医薬品用発酵システム市場規模:製品別
- 下流プロセス製品の市場規模
- 上流プロセス製品の市場規模
・世界のバイオ医薬品用発酵システム市場規模:用途別
- 抗生物質における市場規模
- モノクローナル抗体における市場規模
- プロバイオティクスにおける市場規模
- 組換えタンパク質における市場規模
・世界のバイオ医薬品用発酵システム市場規模:エンドユーザー別
- バイオ医薬品企業における市場規模
- 受託研究機関における市場規模
- 食品産業における市場規模
- 研究開発機関における市場規模
・世界のバイオ医薬品用発酵システム市場規模:地域別
- 南北アメリカのバイオ医薬品用発酵システム市場規模
アメリカのバイオ医薬品用発酵システム市場規模
カナダのバイオ医薬品用発酵システム市場規模
ブラジルのバイオ医薬品用発酵システム市場規模
...
- アジア太平洋のバイオ医薬品用発酵システム市場規模
日本のバイオ医薬品用発酵システム市場規模
中国のバイオ医薬品用発酵システム市場規模
インドのバイオ医薬品用発酵システム市場規模
韓国のバイオ医薬品用発酵システム市場規模
台湾のバイオ医薬品用発酵システム市場規模
...
- ヨーロッパ/中東/アフリカのバイオ医薬品用発酵システム市場規模
イギリスのバイオ医薬品用発酵システム市場規模
ドイツのバイオ医薬品用発酵システム市場規模
フランスのバイオ医薬品用発酵システム市場規模
ロシアのバイオ医薬品用発酵システム市場規模
...
- その他地域のバイオ医薬品用発酵システム市場規模
・競争状況
・企業情報

The Global Biopharmaceutical Fermentation System Market size was estimated at USD 13.51 billion in 2021 and expected to reach USD 14.53 billion in 2022, and is projected to grow at a CAGR 7.72% to reach USD 21.12 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Biopharmaceutical Fermentation System to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Downstream Process Product and Upstream Process Product. The Downstream Process Product is further studied across Chromatography Systems, Consumables and Accessories, and Filtration and Separation Instruments. The Upstream Process Product is further studied across Bioreactors/Fermenters, Buffers, Media and Culture Preparation, and Process Monitoring Systems.

Based on Application, the market was studied across Antibiotics, Monoclonal Antibodies, Probiotics, and Recombinant Proteins.

Based on End User, the market was studied across Biopharmaceutical Companies, Contract Research Organizations, Food Industry, and Research and Development Institutes.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biopharmaceutical Fermentation System market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopharmaceutical Fermentation System Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopharmaceutical Fermentation System Market, including Becton, Danaher Corporation, Dickinson and Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Lonza, Merck KGaA, Nova Biomedicals, Sartorius Stedim, and Thermo Fisher Scientific.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Biopharmaceutical Fermentation System Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopharmaceutical Fermentation System Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopharmaceutical Fermentation System Market?
4. What is the competitive strategic window for opportunities in the Global Biopharmaceutical Fermentation System Market?
5. What are the technology trends and regulatory frameworks in the Global Biopharmaceutical Fermentation System Market?
6. What is the market share of the leading vendors in the Global Biopharmaceutical Fermentation System Market?
7. What modes and strategic moves are considered suitable for entering the Global Biopharmaceutical Fermentation System Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for biotech based drugs
5.1.1.2. Increasing incidences of chronic diseases
5.1.1.3. Rising demand for recombinant drugs or biopharmaceuticals such as proteins, enzymes
5.1.1.4. Development in industrial measurement and monitoring technologies for bio-based production processes
5.1.2. Restraints
5.1.2.1. High cost related with the manufacturing and stringent regulatory requirements
5.1.3. Opportunities
5.1.3.1. Innovations in the production of novel biological drugs
5.1.3.2. New innovations to make efficient and cost-effective fermentation systems
5.1.3.3. Increasing research and developmental activities in different fields of fermentation technology
5.1.4. Challenges
5.1.4.1. Limited awareness and trained professionals in the field for biopharmaceutical fermentation systems
5.2. Cumulative Impact of COVID-19

6. Biopharmaceutical Fermentation System Market, by Product
6.1. Introduction
6.2. Downstream Process Product
6.3.1. Chromatography Systems
6.3.2. Consumables and Accessories
6.3.3. Filtration and Separation Instruments
6.3. Upstream Process Product
6.4.1. Bioreactors/Fermenters
6.4.2. Buffers
6.4.3. Media and Culture Preparation
6.4.4. Process Monitoring Systems

7. Biopharmaceutical Fermentation System Market, by Application
7.1. Introduction
7.2. Antibiotics
7.3. Monoclonal Antibodies
7.4. Probiotics
7.5. Recombinant Proteins

8. Biopharmaceutical Fermentation System Market, by End User
8.1. Introduction
8.2. Biopharmaceutical Companies
8.3. Contract Research Organizations
8.4. Food Industry
8.5. Research and Development Institutes

9. Americas Biopharmaceutical Fermentation System Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Biopharmaceutical Fermentation System Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Biopharmaceutical Fermentation System Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Becton
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Danaher Corporation
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Dickinson and Company
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. F. Hoffmann-La Roche Ltd
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. GE Healthcare
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Lonza
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Merck KGaA
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Nova Biomedicals
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Sartorius Stedim
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Thermo Fisher Scientific
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing